Clostridial toxin treatment for dermatillomania

Details Clostridial toxin treatment for dermatillomania Clostridial toxin treatment for dermatillomania

2008-07-01

2008-07-01

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S234100, C424S236100, C424S239100, C514S002600

Reexamination Certificate

active

07393538

ABSTRACT:
Methods for treating a dermatillomania by local administration of a Clostridial toxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose ofbotulinumtoxin.

REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 2001/0053370 (2001-12-01), Donovan
patent: 2003/0234727 (2003-12-01), Perlman
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 40: 1332-1336, 1990.
Murry et al. Arch. Otolaryngol. Head Neck Surg. 120: 310-316, 1994.
Keythen et al. Psychosomatics 42: 397-403, 2001.
Poungavarin et al. J. Med. Assoc. Thailand 78: 281-288, 1995.
Arnold et al. J. Clin. Psychiatr. 59: 509-514, 1998 (abstract).
Pigott et al. J. Clin. Psychiatr. 55 Suppl. 15-27, 1994.
Kwak, Carolyn H., et al.,Botulinum Toxin in the Treatment of Tics, Arch Neurol., vol. 57, Aug. 2000, pp. 1190-1193.
Pranzatelli, Michael R.,Antidyskinetic Drug Therapy for Pediatric Movement Disorders, Journal of Child Neurology, vol. 11, No. 5, Sep. 1996, pp. 355-369.
Prytz, S., et al.,Treatment of Vocal Tics in Tourette's Syndrome with Injection of Botulinum toxin in the Vocalis Muscle: A Case Report, European Journal of Neurology, 7 (Suppl. 3), 2000, p. 143.
Wang, C. & Curry, L. (Eds.),Tourette Syndrome and Other Tic Disorders: Definitions of Tic Disorders, Tourette Syndrome A Continuing Education Course for Registered Nurses, Tourette Syndrome Association, Southern California Chapter, Oct. 19, 2004, pp. 1-3.
Wang, C. & Curry, L. (Eds.),Symptomatology: Motor and Phonic Tic Manifestations, Tourette Syndrome A Continuing Education Course for Registered Nurses, Tourette Syndrome Association, Southern California Chapter, Oct. 19, 2004, pp. 1-3.
Berkson, Gershon, et al.,Body-Rocking and Other Habits of College Students and Persons With Mental Retardation, American Journal on Mental Retardation, 1999, vol. 104, No. 2, pp. 107-116.
U.S. Appl. No. 10/423,380, filed Apr. 25, 2003, Ackerman, Alan H.
U.S. Appl. No. 10/424,384, filed Apr. 25, 2003, Ackerman, Alan H.
U.S. Appl. No. 10/423,778, filed Apr. 25, 2003, Ackerman, Alan H.
U.S. Appl. No. 10/424,009, filed Apr. 25, 2003, Ackerman, Alan H.
Aoki, K.R. et al., Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions;European Journal Neurology; 2001; 8 (Suppl 5):pp. 21-29.
Aoki, K.R.; Physiology and Pharmacology of Therapeutic Botulinum Neurotoxins; In: Kreyden OP, ed.Hyperhidrosis and Botulinum Toxin in Dermatology; Current Problems in Dermatology: Basel, Karger; 2002; 30: pp. 107-116.
Bigalke, Hans et al., Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture;Brain Res; 1985; 360: pp. 381-424.
Bigalke, H. et al., Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord;Naunyn Schmiedebergs Arch Pharmacol; 1981; 316; pp. 244-251.
Binz, Thomas et al., The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins;J Biochem; (Tokyo) Jun. 5, 1990; 265(16); pp. 9153-9158.
Boyd, R.S., et al., The insulin secreting β-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A.s;Mov Disord; 1995; May; 10(3) p. 376.
Brem, Henry et al., Placebo-controlled trail of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas;The Lancet; vol. 345; Apr. 22, 1995; pp. 1008-1012.
Brin, Mitchell F. et al., Botulinum Toxin Type A: Pharmacology; In: Mayer Nathaniel H, ed.Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin; 2002; pp. 110-124.
Chappell, Phillip et al., Future Therapies of Tourette Syndrome;Neurol Clin; 1997; vol. 15, No. 2, May; pp. 429-450.
Cui, M. et al., Mechanisms of the Antinoceptive Effect of Subcutanous Botox® : Inhibition of Peripheral and Central Nociceptive Processing;Naunyn Schmiedebergs Arch Pharmacol; 2002; 365 (Suppl 2) R17; Abstract.
Dabrowski, E. et al., Botulinum Toxin as a Novel Treatment for Self Mutilation in Lesch-Nyhan Syndrome;Ann Neurol; 2002; 52(3): S157; Abstract.
Diagnostic and Statistical Manual of Mental Disorders4thEd.; Published by the American Psychiatric Association Washington, D.C.; pp. 108-116 and 456-463.
M. J. Duggan, et al., A survey of botulinum neurotoxin substrate expression in cells;Mov Disord; 1995; May; 10(3) p. 376.
Fauci et al.,Harrison's Principles of Internal Medicine; 14thed 1998, contents pages only.
Fung, Lawrence K. et al., Pharmacokinetics of Interstitial Delivery of Carmustine, 4-Hydroperoxycyclophosphamide, and Paclitaxel from a Biodegradable Polymer implant in the Monkey Brain;Cancer Research; 58, Feb. 15, 1998; pp. 672-684.
Guyton, Arthur C. et al.,Textbook of Medical Physiology 10thed; W.B. Saunders Company.
Habermann, E., I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord;Naunyn Schmiedeberg's Arch. Pharmacol; 1974; (281); pp. 47-56.
Habermann, E., Inhibition by tetanus and botulinum A toxin of the release of {3H} noradrenaline and {3H}GABA from rat brain homogenate;Experientia; 1988, Mar. 15; 44(3) pp. 224-226.
Habermann, E. et al., Tetanux Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain;J Neurochem; vol. 51, No. 2 1988; pp. 522-527.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Dystonic Tics;Movement Disorders; vol. 9, No. 3, 1994; pp. 347-349.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Tics Associated with Tourette's Syndrome;Neurology; Apr. 1993; 43(4 Suppl 2); A310; Abstract.
Jankovic, Joseph et al.,Therapy with Botulinum Toxin; Marcel Dekker, Inc.; pp. 5 and 150.
Krauss, Joachim K. et al., Severe Motor Tics Causing Cervical Myelopathy in Tourette's Syndrome;Movement Disorders; vol. 11, No. 5, 1996; pp. 563-565.
Kudelko, K.M. et al., Successful treatment of recalcitrant restless legs syndrome with botulinum toxin A;Movment Disorders; 2002; 17 (Suppl 5); S242 ABS p. 779.
Marjama-Lyons, Jill et al., Tremor-Predominant Parkinson's Disease;Drugs&Aging; 2000; Apr. 16 (4) pp. 273-278.
Moyer, E., et al., Botulinum toxin type B: experimental and clinical experience, Jankovic J., ed.,Neurological Disease and Therapy, Therapy with botulinum toxin, Chp. 6, 1994, 25: pp. 71-85.
Naumann, Markus et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions;European Journal of Neurology; 1999, vol. 6 (suppl 4) pp. S111-115.
Pearce, Bruce et al., Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine;Toxicon; 1997; 35 (9); pp. 1373-1412.
Ragona, Rosario M. et al., Management of Parotid Sialocele With Botulinum Toxin;Laryngoscope; 109; Aug. 1999 (8); pp. 1344-1346.
Sanchez-Prieto, Jose et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes;Eur J Biochem; Jun. 1987; 165 (3): pp. 675-681.
Schantz, Edward J. et al., Properties and Use of Boulinum Toxin and Other Microbial Neurotoxins in Medicine;Microbiol Review; Mar. 1992; 56 (1): pp. 80-99.
Singh, Bal Ram;

Affiliated with

Also associated with

Rating

Clostridial toxin treatment for dermatillomania does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Clostridial toxin treatment for dermatillomania, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clostridial toxin treatment for dermatillomania will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2788733